» Articles » PMID: 15592504

Identification of Membrane Type-1 Matrix Metalloproteinase As a Target of Hypoxia-inducible Factor-2 Alpha in Von Hippel-Lindau Renal Cell Carcinoma

Overview
Journal Oncogene
Date 2004 Dec 14
PMID 15592504
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic renal cell carcinoma (RCC) resulting from the hereditary loss of the von Hippel-Lindau (VHL) tumor suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic tumor(s). VHL functions in the destruction of the alpha subunits of the heterodimeric transcription factor, hypoxia-inducible factor (HIF-1 alpha and HIF-2 alpha), in normoxic conditions. When VHL function is lost, HIF-alpha protein is stabilized, and target hypoxia-inducible genes are transcribed. The process of tumor invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes. Here, we describe a connection between the loss of VHL tumor suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein. Specifically, MT1-MMP is upregulated in VHL-/- RCC cells through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1. Further, we identify a functional HIF-binding site in the proximal promoter of MT1-MMP. To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL tumor suppressor function and an increase in MMP gene and protein expression.

Citing Articles

The Diverse Pathways for Cell Surface MT1-MMP Localization in Migratory Cells.

Kelly H, Inada M, Itoh Y Cells. 2025; 14(3).

PMID: 39937000 PMC: 11816416. DOI: 10.3390/cells14030209.


Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.

Pham D, Hsu T J Biomed Sci. 2025; 32(1):17.

PMID: 39920694 PMC: 11806631. DOI: 10.1186/s12929-024-01111-9.


Modelling the Impact of HIF on Metabolism and the Extracellular Matrix: Consequences for Tumour Growth and Invasion.

Spinicci K, Powathil G, Stephanou A Bull Math Biol. 2025; 87(2):27.

PMID: 39751947 PMC: 11698809. DOI: 10.1007/s11538-024-01391-0.


Development and validation of matrix metalloproteinase for predicting prognosis and tumour microenvironment immune profiles in uterine corpus endometrial carcinoma.

Su H, Yang Y, Li C, Li J, Lv H, Jia X J Cancer. 2024; 15(12):4020-4039.

PMID: 38911387 PMC: 11190773. DOI: 10.7150/jca.91277.


Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.


References
1.
Barry R, Krek W . The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med. 2004; 10(9):466-72. DOI: 10.1016/j.molmed.2004.07.008. View

2.
Kitagawa Y, Kunimi K, Uchibayashi T, Sato H, Namiki M . Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol. 1999; 162(3 Pt 1):905-9. DOI: 10.1097/00005392-199909010-00088. View

3.
Strongin A, Collier I, Bannikov G, Marmer B, Grant G, Goldberg G . Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995; 270(10):5331-8. DOI: 10.1074/jbc.270.10.5331. View

4.
Iliopoulos O, Kibel A, Gray S, Kaelin Jr W . Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995; 1(8):822-6. DOI: 10.1038/nm0895-822. View

5.
Jiang B, Rue E, Wang G, Roe R, Semenza G . Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996; 271(30):17771-8. DOI: 10.1074/jbc.271.30.17771. View